Urolithin A and the standard NAD precursor stack both target mitochondrial aging. Under the model the longevity field used until last year, they were close cousins doing similar work. Under the model the field uses now, they’re doing fundamentally different things. Both can still be useful. The reasons are not what the labels say they are.

This is a post about how to read your own stack when the research framework underneath it just changed.

The old map

For roughly a decade, longevity research operated on the Hallmarks of Aging framework. The original 2013 paper by López-Otín and colleagues listed nine biological processes that go wrong as we age. Genomic instability. Telomere attrition. Epigenetic alterations. Loss of proteostasis. Deregulated nutrient sensing. Mitochondrial dysfunction. Cellular senescence. Stem cell exhaustion. Altered intercellular communication. The 2023 update added three more.

The framework was useful, and it produced a clear product logic. If aging is a list of broken pathways, you build a stack by picking compounds that target each one. NMN or NR for NAD-dependent pathways. Senolytics for cellular senescence. Rapamycin for nutrient sensing through mTOR. Spermidine for autophagy. Resveratrol for sirtuins. Each pick is a hammer for one nail, and the stack is the toolbox.

Most longevity content from the last five years is built on this logic, whether or not the creators name the framework directly. It also scales nicely into a product market because it gives every supplement a story. Pathway X is broken, this compound fixes it.

What changed in April 2026

The Targeting Longevity 2026 conference, held in early April, was the public surfacing of a shift that had been building in the literature for two years. The new framing isn’t that the hallmarks are wrong. They’re real, and they still describe things that go wrong. The shift is about what to do about it.

The argument that gathered consensus is roughly this. Aging is not best understood as a list of independent failures. It’s better understood as a progressive loss of coordination between biological systems that previously regulated each other. When the field tried to fix hallmarks one at a time in trials, single-target interventions kept underperforming. Trials targeting multiple pathways simultaneously, including inflammation, senescence, mitochondrial function, and nutrient signaling, kept outperforming the single-target ones, even when the multi-target dose of each component was lower.

The reframing is from “fix the pathway” to “restore the coordination.” It changes what counts as a good intervention. Under the old map, hitting one hallmark cleanly was the win. Under the new map, an intervention that touches three pathways at moderate strength and helps them re-coordinate is more interesting than an intervention that hits one pathway hard.

That sounds like a small shift. It isn’t. It changes which compounds are doing what the field now thinks actually works.

Reading the cabinet against the new map

GLP-1 agonists. Under the old map, semaglutide and tirzepatide were metabolic drugs with a side effect of weight loss. Under the new map, the human data from the past 18 months reframes them. They reduce systemic inflammation, normalize nutrient signaling, improve cardiovascular markers, and influence mitochondrial function downstream of metabolic normalization. That’s four hallmarks moving in coordination, which is exactly the profile the new framework rewards. The drug class quietly became a longevity intervention before anyone in the consumer longevity space caught up to calling it one.

Urolithin A. This was always sold as a niche mitochondrial supplement, the kind of thing that showed up in ingredient lists with a paragraph nobody reads. Under the new map it has a cleaner story. Its mechanism is mitophagy, which is the cellular process of culling damaged mitochondria so the system can re-coordinate around healthy ones. It isn’t fixing a broken pathway. It’s helping the body restore the quality control that lets the system run itself. The cardiac protection data published this spring fits that mechanism. Urolithin A is doing something the new framework specifically values, and the labels have not caught up.

NAD precursors (NMN and NR). This is the category that loses the most narrative under the new map, but it doesn’t lose all of it. Under the old map, NAD precursors were a flagship intervention because NAD-dependent enzymes touch many pathways, so raising NAD looked like raising the floor on multiple hallmarks at once. Under the new map, simply elevating a single substrate without addressing why coordination broke down is a tactical tweak rather than a primary intervention. NAD precursors still seem to do useful things, but they’re doing narrower work than the marketing implies. If you’ve been holding NMN as the cornerstone of your stack, the new framework would say it’s a supporting actor, not the lead.

Rapamycin. This is the interesting one. The old map placed rapamycin in the nutrient-sensing bucket because it inhibits mTOR. That framing always undersold what it does. mTOR sits upstream of autophagy, protein synthesis, immune function, and metabolic regulation, which means a compound that modulates it touches multiple coordinated systems by design. Rapamycin was always defensible because it was a coordination intervention pretending to be a single-pathway one. The new map makes its case stronger, not weaker. The remaining question is dosing, which the new framework suggests should be low and pulsed rather than high and continuous.

Why the consumer side hasn’t caught up

The lag between research consensus and supplement market is usually about 18 months. That’s the time it takes for a shift to filter through review papers, conference talks, podcast circuits, and into product pages. This particular shift is harder to translate than usual for two reasons.

First, the new map doesn’t generate a clean shopping list. “Restore coordination” doesn’t fit on a label as well as “supports cellular energy” or “promotes healthy aging pathways.” The marketing language for systems-level thinking hasn’t been written yet.

Second, the supplement market has structural reasons to keep selling what it already manufactures. Inventory exists. Studies are already cited. Reframing a flagship NAD product as “supporting actor in a coordination protocol” is not a marketing department’s idea of an upgrade.

Neither of those is anyone’s fault. It’s how the pipeline works. But it does mean that for the next 12 to 18 months, the gap between what the research community considers the best framework and what consumers can buy off the shelf is going to be unusually wide.

What to do with this

If you have a stack, the new map suggests an audit rather than a teardown. Compounds that touch multiple coordinated systems at moderate doses (GLP-1s if accessible, urolithin A, low-pulsed rapamycin if you have a clinician willing) get more interesting. Single-pathway maximalist plays (high-dose NMN as a foundation, single-target senolytics on a schedule) become tactical rather than central. Lifestyle interventions that operate at the systems level by definition (sleep regularity, fasting protocols, zone 2 cardio, resistance training) become structurally more important under the new framework, not less, because they’re coordination interventions that nothing in a bottle replicates.

The takeaway isn’t that anyone selling you longevity products in 2025 was wrong. They were optimizing against the best available map. The map has updated. The cabinet should slowly update with it, but it doesn’t need to be thrown out tomorrow.

The more useful question is whether you’ve noticed the new map exists, because the supplement aisle won’t tell you for at least another year.